Search

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

Internal Teat Sealant for Dairy Cows | Boehringer Ingelheim US

Boehringer Ingelheim adds internal teat sealant to their dairy mastitis portfolio, with a more ergonomic design and improved removal process.

Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis

Biosimilars

: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Full data announced in DINAMO trial in young people with T2D

Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

OFEV® (nintedanib) Now Available in the United States

Redefining mental health to enable people to thrive

At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Parasiticides

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

MASH

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

An Eye for the Big Picture | PDF

Current & Future Options for COVID-19

biusa-hp-iu-dress-for-your-day-guidelines.pdf

Bi Inforgraphic biosimilar Data

Patient information

Gilotrif-LongForm.pdf

Glyxambi-LongForm.pdf

Jardiance-LongForm.pdf

Jentadueto-LongForm.pdf

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

Internal Teat Sealant for Dairy Cows | Boehringer Ingelheim US

Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis

Biosimilars

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Biosimilars

Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge

Full data announced in DINAMO trial in young people with T2D

New agreement with Quallent expands biosimilar access

OFEV® (nintedanib) Now Available in the United States

Redefining mental health to enable people to thrive

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Parasiticides

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

MASH

Our Curiosity Never Stops | Boehringer Ingelheim US

An Eye for the Big Picture | PDF

Current & Future Options for COVID-19

biusa-hp-iu-dress-for-your-day-guidelines.pdf

Bi Inforgraphic biosimilar Data

Patient information

Gilotrif-LongForm.pdf

Glyxambi-LongForm.pdf

Jardiance-LongForm.pdf

Jentadueto-LongForm.pdf